Patents Examined by Delia M. Ramirez
  • Patent number: 10975363
    Abstract: Provided herein are novel, synthetic polypeptides having, for example, acyl-acyl carrier protein (ACP) thioesterase (TE) activity, including polypeptides that convert pimeloyl-ACP to pimelic acid. In some aspects, the synthetic polypeptides have advantageous enzymatic activity and/or improved substrate specificity relative to a wild type acyl-ACP TE.
    Type: Grant
    Filed: April 1, 2019
    Date of Patent: April 13, 2021
    Assignee: INV Nylon Chemicals Americas, LLC
    Inventors: Alexander Brett Foster, Arghya Barman, Jonathan Kennedy, Paul S. Pearlman
  • Patent number: 10968469
    Abstract: The present invention relates to the use of a protein as a hydroxylase, a host cell comprising the protein, the use of the protein or host cell in the production of hydroxy-pipecolic acid (HPA), a method of production HPA, methods of producing the protein, a mutant protein and a nucleic acid encoding the mutant protein and a vector comprising a nucleic acid encoding the protein.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: April 6, 2021
    Assignee: F. Hoffmann-La Roche, Inc.
    Inventors: Mara Boenitz-Dulat, Hans Iding, Dennis Wetzl, Alessa Hinzmann
  • Patent number: 10961286
    Abstract: The present invention relates to a nucleic acid construct having a chimeric nucleic acid molecule comprising a first nucleic acid moiety encoding an amphipathic shield domain protein; a second nucleic acid moiety encoding an integral membrane protein; and a third nucleic acid moiety encoding a water soluble expression decoy protein, as well as a chimeric nucleic acid molecule having a first nucleic acid moiety encoding an amphipathic shield domain protein and a second nucleic acid moiety encoding an integral membrane protein. The present invention further relates to an expression vector, a host cell, and a protein encoded by the nucleic acid construct. Also disclosed is a method of recombinantly producing an integral membrane protein in soluble form.
    Type: Grant
    Filed: August 14, 2015
    Date of Patent: March 30, 2021
    Assignee: Cornell University
    Inventors: Matthew Delisa, Dario Mizrachi
  • Patent number: 10961517
    Abstract: The present invention relates to non-naturally occurring polypeptides useful for preparing armodafinil, polynucleotides encoding the polypeptides, and methods of using the polypeptides. The non-naturally occurring polypeptides of the present invention are effective in carrying out biocatalytic conversion of the (i) 2-(benzhydrylsulfinyl)acetamide to (?)-2-[(R)-(diphenylmethyl)sulfinyl]acetamide (armodafinil), or (ii) benzhydryl-thioacetic acid to (R)-2-(benzhydrylsulfinyl)acetic acid, which is a pivotal intermediate in the synthesis of armodafinil, in enantiomeric excess.
    Type: Grant
    Filed: August 17, 2020
    Date of Patent: March 30, 2021
    Assignee: Codexis, Inc.
    Inventors: Ee Lui Ang, Oscar Alvizo, Behnaz Behrouzian, Michael D. Clay, Steven J. Collier, Ellen D. Eberhard, Fu Fan, Shiwei Song, Derek J. Smith, Magnus Widegren, Robert Wilson, Junye Xu, Jun Zhu
  • Patent number: 10955416
    Abstract: Novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have now been identified in human solid tumors, e.g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFG). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant polypeptides, probes for detecting it, isolated mutant polypeptides, and reagents for detecting the fusion and truncated polypeptides.
    Type: Grant
    Filed: February 16, 2018
    Date of Patent: March 23, 2021
    Assignee: Cell Signaling Technology, Inc.
    Inventors: Klarisa Rikova, Herbert Haack, Laura Sullivan, Ailan Guo, Anthony Possemato, Joan MacNeill, Ting-Lei Gu, Jian Yu
  • Patent number: 10947572
    Abstract: The present disclosure provides engineered polypeptides having imine reductase activity, polynucleotides encoding the engineered imine reductases, host cells capable of expressing the engineered imine reductases, and methods of using these engineered polypeptides with a range of ketone and amine substrate compounds to prepare secondary and tertiary amine product compounds.
    Type: Grant
    Filed: August 25, 2020
    Date of Patent: March 16, 2021
    Assignee: Codexis, Inc.
    Inventors: Haibin Chen, Steven J. Collier, Jovana Nazor, Joly Sukumaran, Derek Smith, Jeffrey C. Moore, Gregory Hughes, Jacob Janey, Gjalt W. Huisman, Scott J. Novick, Nicholas J. Agard, Oscar Alvizo, Gregory A. Cope, Wan Lin Yeo, Stefanie Ng Minor
  • Patent number: 10927351
    Abstract: The present disclosure provides engineered ketoreductase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase enzyme. Also provided are polynucleotides encoding the engineered ketoreductase enzymes, host cells capable of expressing the engineered ketoreductase enzymes, and methods of using the engineered ketoreductase enzymes to synthesize a variety of chiral compounds.
    Type: Grant
    Filed: January 22, 2019
    Date of Patent: February 23, 2021
    Assignee: Codexis, Inc.
    Inventors: Jack Liang, Stephane J. Jenne, Emily Mundorff, Charlene Ching, John M. Gruber, Anke Krebber, Gjalt W. Huisman
  • Patent number: 10913960
    Abstract: A microbial cell, which is genetically modified to increase the expression relative to the corresponding genetically unmodified cell of an AlkB alkane hydroxylase (Eb) having an amino acid sequence at least 95% identical with the amino acid sequence of SEQ ID NO: 1 and a wax-ester synthase (Ef) having an amino acid sequence at least 95% identical with the amino acid sequence of SEQ ID NO: 2. The cell does not have a genetic modification that increases formation of a carboxylic acid or a carboxylate ester from a simple carbon source.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: February 9, 2021
    Assignee: Evonik Operations GmbH
    Inventors: Steffen Schaffer, Thomas Haas, Wilhelm Bruegging, Ralf Meier
  • Patent number: 10899544
    Abstract: Yeast cells are genetically modified to disrupt a native metabolic pathway from dihydroxyacetone to glycerol. In certain aspects, the yeast cell is of the genera Kluyveromyces, Candida or Issatchenkia. In other aspects, the yeast cell is capable of producing at least one organic acid, such as lactate. The yeast cells produce significantly less glycerol than the wild-type strains, and usually produce greater yields of desired fermentation products. Yeast cells of the invention often grow well when cultivated, despite their curtailed glycerol production.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: January 26, 2021
    Assignee: CARGILL, INCORPORATED
    Inventors: Catherine Asleson Dundon, Pirrko Suominen, Aristos Aristidou, Brian J. Rush, Kari Koivuranta, Benjamin Matthew Hause, Thomas William McMullin, Kevin Roberg-Perez
  • Patent number: 10883127
    Abstract: Described herein are variants of acetylserotonin O-methyltransferase (ASMT) as well as vectors and recombinant microbial host cells expressing such ASMT variant and their use in producing melatonin and related compounds. Preferred ASMT variants provide for a higher turnover of N-acetylserotonin into melatonin.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: January 5, 2021
    Assignee: Danmarks Tekniske Universitet
    Inventor: Hao Luo
  • Patent number: 10883130
    Abstract: The present disclosure relates to the production of steviol glycosides rebaudioside J and rebaudioside N through the use of rebaudioside A as a substrate and a biosynthetic pathway involving various 1,2 RhaT-rhamnosyltransferases.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: January 5, 2021
    Assignee: Conagen Inc.
    Inventors: Guohong Mao, Michael Batten, Phillip Hunt, Oliver (Xiaodan) Yu
  • Patent number: 10876098
    Abstract: The invention relates to an unspecific peroxygenase of the Agrocybe aegerita fungus, obtained by means of directed molecular evolution to facilitate the functional expression thereof in an active, soluble and stable form. The peroxygenase described in the invention shows a significant improvement in the functional expression thereof, improved monooxygenase activity and reduced peroxidase activity, in relation to the monooxygenase and peroxidase activities showed by the unspecific wild-type peroxygenase of A. aegerita. The peroxygenase of the invention is useful in chemical processes, including industrial transformations such as the selective oxyfunctionalisation of carbon-hydrogen bonds of various organic compounds.
    Type: Grant
    Filed: November 14, 2016
    Date of Patent: December 29, 2020
    Assignee: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)
    Inventors: Patricia Molina Espeja, Francisco José Plou Gasca, Miguel Alcalde Galeote, Patricia Gómez De Santos
  • Patent number: 10870892
    Abstract: Novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have been identified herein in human solid tumors, e.g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFC). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ALK kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: December 22, 2020
    Assignee: CELL SIGNALING TECHNOLOGY, INC.
    Inventors: Klarisa Rikova, Herbert Haack, Laura Sullivan, Ailan Guo, Anthony Possemato, Joan MacNeill, Ting-Lei Gu, Jian Yu
  • Patent number: 10858405
    Abstract: The present invention relates to new EGFR binding molecules based on ubiquitin muteins (Affilin®), preferably Affilin molecules having a characteristic three amino acid residue motif. The invention further refers to EGFR binding molecules that bind to different or non-overlapping epitopes than the anti-EGFR monoclonal antibody Cetuximab. The invention further relates to the use of these EGFR binding proteins in medicine, preferably for use in the diagnosis or treatment of cancer.
    Type: Grant
    Filed: February 4, 2016
    Date of Patent: December 8, 2020
    Assignee: Navigo Proteins GmbH
    Inventors: Eva Bosse-Doenecke, Florian Settele, Erik Fiedler, Ulrich Haupts
  • Patent number: 10858662
    Abstract: The present invention relates to a method for regulating gene expression, comprising introducing into a cell each of a recombinant vector which expresses a first domain comprising N-terminus of a Cas9 protein, and a recombinant vector which expresses a second domain comprising C-terminus of a Cas9 protein, a composition comprising the recombinant vectors, a kit for regulating gene expression, and a method for intracellular production of Cas9 protein. Moreover, the present invention relates to a transformed cell introduced with a viral vector which packages the first domain, and a viral vector which packages the second domain, and to a composition comprising a virus produced therefrom.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: December 8, 2020
    Assignee: INSTITUTE FOR BASIC SCIENCE
    Inventors: Jin Soo Kim, Tae Young Koo
  • Patent number: 10858678
    Abstract: A method of producing 3-oxoadipic acid from an aliphatic compound easily utilizable by a microorganism, such as a saccharide, by utilization of a metabolic pathway of the microorganism is disclosed.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: December 8, 2020
    Assignee: TORAY INDUSTRIES, INC.
    Inventors: Kyohei Isobe, Kenji Kawamura, Masateru Ito, Katsushige Yamada
  • Patent number: 10820599
    Abstract: The present invention is related to an enzyme that allows efficient removal of fructan from grain and vegetable raw material. The enzyme according to the invention produces grain and vegetable material having a fructan content significantly lower compared to that of the starting material.
    Type: Grant
    Filed: June 12, 2020
    Date of Patent: November 3, 2020
    Assignee: Oy Karl Fazer Ab
    Inventors: Jussi Loponen, Markku Mikola, Juhani Sibakov
  • Patent number: 10822593
    Abstract: The present disclosure discloses an alcohol dehydrogenase mutant and application thereof in synthesis of diaryl chiral alcohols, and belongs to the technical field of bioengineering. The alcohol dehydrogenase mutant of the present disclosure has excellent catalytic activity and stereoselectivity, and may efficiently catalyze the preparation of a series of chiral diaryl alcohols in R- and S-configurations. By coupling alcohol dehydrogenase of the present disclosure to glucose dehydrogenase or formate dehydrogenase, the synthesis of chiral diaryl alcohol intermediates of various antihistamines may be achieved. Compared with the prior art, a method for preparing diaryl chiral alcohols through asymmetric catalytic reduction using the alcohol dehydrogenase of the present disclosure has the advantages of simple and convenient operation, high substrate concentration, complete reaction and high product purity, and has great industrial application prospects.
    Type: Grant
    Filed: July 25, 2019
    Date of Patent: November 3, 2020
    Assignee: Jiangnan University
    Inventors: Ye Ni, Jieyu Zhou, Guochao Xu, Yue Wang
  • Patent number: 10815476
    Abstract: The present invention provides sequence specific restriction enzymes for site-specific cleavage of RNA, as well as methods of their use.
    Type: Grant
    Filed: June 28, 2018
    Date of Patent: October 27, 2020
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Zefeng Wang, Rajarshi Choudhury
  • Patent number: 10808234
    Abstract: The invention is directed to novel amylases.
    Type: Grant
    Filed: May 2, 2019
    Date of Patent: October 20, 2020
    Assignee: Fornia BioSolutions, Inc.
    Inventors: Xiyun Zhang, Jie Yang, Khin Oo, Goutami Banerjee, Tatsuya Fukushima, Eric Lin Hu, Marielle De Jesus Palatino, Jijiao Zeng, Imad N. Sawaya